Related Experiment Video
Updated: May 27, 2026
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
Published on: August 1, 2025
Developing dendritic cell-based therapies to condition immune responses to novel oncogenic proteins and stem cells
Anupama Sharma1, Brian J Czerniecki
1Research and Department of Surgery, Rena Rowan Breast Center, Abramson Cancer Center, PENN Medicine, University of Pennsylvania, PA, USA. sharmaa@uphs.upenn.edu.
Abstract:
Cancer vaccines have been disappointing when utilized as stand-alone therapy, especially in late disease settings. However, recent clinical studies in prostate cancer have suggested that dendritic cellular (DC) vaccines may impact patient survival, reviving the notion that cancer vaccines can impact established cancer. In this review we will highlight the advances that have been made in the development of DC-based therapies activated by Toll-like receptor agonists with the capacity to condition toward strong Th1 cellular responses, through the production of cytokines and chemokines, and a capacity to induce apoptosis of tumor cells. Used in early cancer settings, these DCs induce clinically effective immune responses, thus shifting the emphasis toward using these cells earlier in the disease process. We will also discuss targeting novel molecules and cancer stem cells that can eliminate cells with high metastatic potential, moving DC-based therapies into mainstream cancer therapy.
Insights
Dendritic cell (DC) vaccines show promise in treating established cancers, particularly when used early. Advances in DC-based therapies activate immune responses and target cancer stem cells for improved survival.
Area of Science:
- Immunology
- Oncology
- Vaccine Development
Background:
- Cancer vaccines have historically shown limited efficacy as monotherapy, especially in advanced stages.
- Recent prostate cancer studies suggest dendritic cell (DC) vaccines can improve patient survival, indicating potential against established disease.
Purpose of the Study:
- To review advances in dendritic cell (DC)-based cancer therapies.
- To highlight the potential of DC vaccines in early-stage cancer treatment and their ability to target cancer stem cells.
Main Methods:
- Review of clinical studies and therapeutic strategies involving DC-based vaccines.
- Focus on DC activation via Toll-like receptor agonists to induce Th1 cellular responses.
- Discussion of targeting novel molecules and cancer stem cells for enhanced metastatic potential elimination.
Main Results:
- DC-based therapies activated by Toll-like receptor agonists can induce strong Th1 responses, cytokine/chemokine production, and tumor cell apoptosis.
- Early application of these DC vaccines has led to clinically effective immune responses.
- Targeting cancer stem cells shows potential for eliminating highly metastatic cells.
Conclusions:
- Dendritic cell (DC) vaccines are a promising avenue for cancer therapy, especially when administered in early disease stages.
- Advances in DC activation and targeting of cancer stem cells may position DC-based therapies for mainstream cancer treatment.
- The review emphasizes a shift towards earlier intervention with DC-based immunotherapies.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...